TAM22H62 RSF S.L.C.

117TH CONGRESS 2D SESSION	<b>S.</b>

To improve the requirements for making a determination of interchangeability of a biological product and its reference product.

## IN THE SENATE OF THE UNITED STATES

Mr. Lee introduced the following b	ill; which	was read	twice and	referred	te
the Committee on					

## A BILL

To improve the requirements for making a determination of interchangeability of a biological product and its reference product.

- 1 Be it enacted by the Senate and House of Representa-
- 2 tives of the United States of America in Congress assembled,
- 3 SECTION 1. SHORT TITLE.
- 4 This Act may be cited as the "Biosimilar Red Tape
- 5 Elimination Act".
- 6 SEC. 2. BIOSIMILAR BIOLOGICAL PRODUCTS.
- 7 Section 351(k) of the Public Health Service Act (42
- 8 U.S.C. 262(k)) is amended—
- 9 (1) in paragraph (2)(A)(i)(I)(bb), by striking ";
- and" and inserting "; or"; and

1	(2) in paragraph (4)—
2	(A) at the end of subparagraph (A)(ii), by
3	striking "; and" and inserting a period;
4	(B) by striking "sufficient to show" and all
5	that follows through "(A) the biological prod-
6	uct—" and inserting "sufficient to show that
7	the biological product—";
8	(C) by striking "Upon review of an" and
9	inserting the following:
10	"(A) In general.—Upon review of an";
11	and
12	(D) by amending subparagraph (B) to
13	read as follows:
14	"(B) CERTAIN STUDIES NOT REQUIRED.—
15	The Secretary may not require, for a deter-
16	mination of interchangeability described in sub-
17	paragraph (A), that a biological product under-
18	go studies that assess the risks of alternating or
19	switching between use of the biological product
20	and the reference product.".